Epidemiological Characteristics of Meningococcal Meningitis (2016 to 2018) Four Years after the Introduction of Serogroup A Meningococcal Conjugate Vaccine in Benin

被引:1
|
作者
Godjedo, Togbemabou Primous Martial [1 ,2 ]
Agbankpe, Alidehou Jerrold [3 ]
Paraiso, Moussiliou Noel [4 ]
Dougnon, Tamegnon Victorien [3 ]
Hidjo, Marie [3 ]
Baba-Moussa, Lamine [5 ]
Bankole, Honore [1 ,3 ]
机构
[1] Minist Publ Hlth, Epidmiol Surveillance Serv, Cotonou, Benin
[2] Minist Publ Hlth, Natl Hlth Lab, Cotonou, Benin
[3] Univ Abomey Calavi, Res Lab Appl Biol, Polytech Sch Abomey Calavi, Res Unit Appl Microbiol & Pharmacol Nat Subst, Cotonou, Benin
[4] Univ Abomey Calavi, Reg Inst Publ Hlth, Cotonou, Benin
[5] Univ Abomey Calavi, Lab Biol & Mol Typing Microbiol, Fac Sci & Technol, Cotonou, Benin
来源
ADVANCES IN PUBLIC HEALTH | 2020年 / 2020卷
关键词
BACTERIAL-MENINGITIS; COUNTRIES; BELT; SURVEILLANCE; AFRICA;
D O I
10.1155/2020/1932940
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives. This study aims to study the epidemiological and geographic characteristics of the meningococcal serogroups four years after the introduction of serogroup A meningococcal conjugate vaccine.Methods. This is a prospective, descriptive, analytical study, and it took place from 2016 to 2018. Cerebrospinal fluid (CSF) samples were taken after the identification of meningitis cases. The samples, thus, taken were sent to the laboratory for culture and identification ofNeisseria meningitidisin accordance with WHO standards.Results. Eight hundred and ninety-nine bacterial strains were identified, of which 219 were strains ofNeisseria meningitidis. The majority ofN. meningitidis-positive samples were from male patients (59.8%) with a median age of 4 (IQR: 1-13). Four ofN. meningitidisserogroups were identified, namely, serogroups C (6.8%), W (19.6%), X (1.8%), and A (0.5%). Geographically, 92.7% of the identifiedN. meningitidisserogroups came from patients who lived in the northern region of the country. The departments most concerned were Alibori (N. meningitidisC (66.7%) andN. meningitidisW (20.9%)); Atacora (N. meningitidisW (41.9%),N. meningitidisX (75.0%), andN. meningitidisC (13.3%)); and Borgou (N. meningitidisW (23.3%)).Conclusion. The results of this study showed that there is an emergence of cases of meningococcal of serogroup C four years after the introduction of MenAfricVac in Benin. These results demonstrated the effectiveness of case-by-case surveillance in detecting small changes in the distribution of serogroups that could have important implications for public health strategies in the coming seasons.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine
    Snape, MD
    Kelly, DF
    Green, B
    Moxon, ER
    Borrow, R
    Pollard, AJ
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (02) : 128 - 131
  • [42] Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine
    Sakou, Irine-Ikbale
    Tzanakaki, Georgina
    Tsolia, Maria N.
    Sioumala, Maria
    Barbouni, Anastasia
    Kyprianou, Miltiades
    Papaevangelou, Vana
    Tsitsika, Artemis
    Blackwell, Caroline C.
    Kafetzis, Dimitris
    Kremastinou, Jenny
    VACCINE, 2009, 27 (33) : 4408 - 4411
  • [43] Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme
    Goncalves, Paulo
    Saez-Lopez, Emma
    Carneiro, Sofia
    Simoes, Maria Joao
    PLOS ONE, 2021, 16 (04):
  • [44] Invasive meningococcal disease in Shanghai, China from 1950 to 2016: implications for serogroup B vaccine implementation (vol 8, 12334, 2018)
    Chen, Mingliang
    Rodrigues, Charlene M. C.
    Harrison, Odile B.
    Zhang, Chi
    Tan, Tian
    Chen, Jian
    Zhang, Xi
    Chen, Min
    Maiden, Martin C. J.
    SCIENTIFIC REPORTS, 2018, 8
  • [45] Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
    Yaro, Seydou
    Lafourcade, Berthe-Marie Njanpop
    Ouangraoua, Soumeya
    Ouoba, Aline
    Kpoda, Herve
    Findlow, Helen
    Tall, Haoua
    Seanehia, Joy
    Martin, Catherine
    Ouedraogo, Jean-Bosco
    Gessner, Bradford
    Meda, Nicolas
    Borrow, Ray
    Trotter, Caroline
    Mueller, Judith E.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 (03) : 435 - 443
  • [47] Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014
    Djingarey, Mamoudou H.
    Diomande, Fabien V. K.
    Barry, Rodrigue
    Kandolo, Denis
    Shirehwa, Florence
    Lingani, Clement
    Novak, Ryan T.
    Tevi-Benissan, Carol
    Perea, William
    Preziosi, Marie-Pierre
    LaForce, F. Marc
    CLINICAL INFECTIOUS DISEASES, 2015, 61 : S434 - S441
  • [48] CLINICAL AND ECONOMIC IMPACT OF THE INTRODUCTION OF THE VACCINE AGAINST MENINGOCOCCAL MENINGITIS C IN CHILDREN AGED 0-4 YEARS IN BRAZIL
    Andrade, T. R.
    Sansone, D.
    Etto, H.
    Decimoni, T. C.
    Araujo, G. T.
    Fonseca, M.
    VALUE IN HEALTH, 2015, 18 (03) : A255 - A255
  • [49] Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso-Implications for introduction of PsA-TT into the Expanded Programme on Immunization
    Meyer, Sarah A.
    Kambou, Jean Ludovic
    Cohn, Amanda
    Goodson, James L.
    Flannery, Brendan
    Medah, Isaie
    Messonnier, Nancy
    Novak, Ryan
    Diomande, Fabien
    Djingarey, Mamoudou H.
    Clark, Thomas A.
    Yameogo, Issaka
    Fall, Amadou
    Wannemuehler, Kathleen
    VACCINE, 2015, 33 (12) : 1492 - 1498
  • [50] The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt
    Nakhla, I
    Frenck, RW
    Teleb, NA
    El Oun, S
    Sultan, Y
    Mansour, H
    Mahoney, F
    VACCINE, 2005, 23 (25) : 3288 - 3293